SCHEMBL25711918

SCHEMBL25711918

CC(C)(C)OC(=O)NC(CC=O)CSc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.50
▸ PPARA Q07869 5/20 0.45
▸ PPARG P37231 4/20 0.45
▸ MTNR1A P48039 3/20 0.44
▸ MTNR1B P49286 3/20 0.44
▸ PPARD Q03181 2/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ CTSS P25774 3/20 0.42
▸ CTSK P43235 3/20 0.42
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ APP P05067 1/20 0.40
▸ F2 P00734 1/20 0.39
▸ PRSS1 P07477 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19014798 1.00 ATM (0.50) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL2945955 0.86 ATM (0.50) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL28499654 0.85 ATM (0.49) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL22409416 0.85 PLA2G10 (0.50) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL22409417 0.85 PLA2G10 (0.50) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL22203002 0.84 ATM (0.48) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL22202987 0.84 ATM (0.48) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL7321063 0.84 ATM (0.64) ATMPPARAPPARGPPARDSYK
SCHEMBL22409489 0.84 ATM (0.48) ATMPPARAPPARGMTNR1AMTNR1B
SCHEMBL19014888 0.84 ATM (0.48) ATMPPARAPPARGMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
EP-4522154-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
CN-112105360-B BCL-2 protein degrading agent for cancer treatment 生物风险投资有限责任公司 2024-01-30 — — CN disclosed
WO-2023220425-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed
WO-2023107606-A1 BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-15 — — WO disclosed
CN-112105360-A BCL-2 protein degrading agents for cancer treatment 生物风险投资有限责任公司 2020-12-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 ATM 3487/4885PPARA 2731/4885PPARG 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback